Navigation Links
Valeant Pharmaceuticals to Announce 2009 Second Quarter Results on August 4, 2009
Date:7/21/2009

ALISO VIEJO, Calif., July 21 /PRNewswire-FirstCall/ --Valeant Pharmaceuticals International (NYSE: VRX) today announced that it will host a conference call and a live Internet webcast along with a slide presentation on Tuesday, August 4, 2009 at 10:00 a.m. EDT (7:00 a.m. PDT) to discuss results for the 2009 second quarter.

The dial-in number to participate on this call is (877) 295-5743, confirmation code 20797641. International callers should dial (973) 200-3961, confirmation code 20797641. A replay will be available approximately two hours following the conclusion of the conference call to Tuesday, August 18, 2009, and can be accessed by dialing (800) 642-1687 or (706) 645-9291, confirmation code 20797641.

The webcast and slide presentation will be hosted in the investor relations section of its corporate Web site at www.valeant.com. Participants should allow approximately five to 10 minutes prior to the call's start time to visit the site and to download any streaming media software needed to listen to the Internet webcast. An online archive of the webcast will be available following the end of the live call in the webcast archive portion of the investor relations section at www.valeant.com.

About Valeant

Valeant Pharmaceuticals International (NYSE: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at www.valeant.com.

    Contact:
    Laurie W. Little
    949-461-6002
    laurie.little@valeant.com

(Logo: http://www.newscom.com/cgi-bin/prnh/20081125/VALEANTLOGO)


'/>"/>
SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Valeant Grants Schering-Plough Exclusive Option in Japan for Taribavirin in Exchange for Release of Last Right of Refusal
2. Valeant Announces Increase to Securities Repurchase Program
3. Valeant to Acquire Polish Dermatology Company
4. Valeant Pharmaceuticals to Present at Bank of America and Merrill Lynch 2009 Health Care Conference
5. Valeant Pharmaceuticals Highlights Taribavirin Phase IIb 60-Week Data Presentation at European Association for the Study of Liver (EASL) Annual Meeting
6. Valeant Pharmaceuticals to Announce 2009 First Quarter Results on May 5, 2009
7. Valeant Pharmaceuticals Appoints President of Valeant Pharmaceuticals International
8. Valeant Pharmaceuticals to Present at Cowen and Company 29th Annual Health Care Conference
9. Valeant Pharmaceuticals Announces Annual Stockholder Meeting Date
10. Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results
11. Valeant Pharmaceuticals to Announce 2008 Fourth Quarter and Year Results on February 24, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... ... March 30, 2017 , ... According to the American ... each year, putting it among the top 5 most popular minimally-invasive cosmetic procedures in ... million-plus procedures will be performed over the next 8-10 weeks. For anyone considering a ...
(Date:3/30/2017)... NC (PRWEB) , ... March 30, 2017 , ... ... will host the live audio conference “ Preventing Hospital Readmissions Through Discharge Planning ... 12, 2017 at 1:00 pm ET. This conference discusses strategies to prevent readmissions ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... squash, announced it has enlisted New York City-based sports and entertainment marketing firm ... and procure sponsorship opportunities for the Professional Squash Association (PSA), which includes first-time ...
(Date:3/29/2017)... St. Petersburg, FL (PRWEB) , ... March 30, 2017 , ... ... Often called the "Spice of Life" or "Wonder Spice", it has been used for ... extensive use in the East," says Heshelow, author of " Turmeric: How to Use ...
(Date:3/29/2017)... IN (PRWEB) , ... March 29, 2017 , ... ... Study, this webinar provides insight into the challenges employers face in trying to ... complexity of managing employee benefits programs? Adding to the growing complexity, companies ...
Breaking Medicine News(10 mins):
(Date:3/30/2017)... March 30, 2017  Lannett Company, Inc. (NYSE: ... made a $25 million payment against its existing revolving ... combined with the $75 million payment we made earlier ... million in annualized cash interest expense, at current rates" ... Lannett.  "Our business is solid and we continue to ...
(Date:3/29/2017)... , Mar. 29, 2017 Research ... Neuromonitoring (IONM) Market Size & Forecast By Type (Insource IONM, ... 2025" report to their offering. ... The global Intraoperative Neuromonitoring ... 2025. The intraoperative neuromonitoring market is anticipated to witness significant ...
(Date:3/29/2017)... , March 29, 2017 Global intravenous (IV) iron ... billion by 2021, growing at a CAGR of 5%. ... by a doctor to treat anemia or other iron deficiencies. ... in the body. However, in some cases, oral administrations are ... and intravenous (IV) iron therapy comes into the picture. ...
Breaking Medicine Technology: